Skip to main content
Clinical Trials/ISRCTN01253916
ISRCTN01253916Completed未知

AntiEpileptic drug Monitoring in PREgnancy: an evaluation of effectiveness, costeffectivenessand acceptability of monitoring strategies

Queen Mary, University of London0 sites1,000 target enrollmentStarted: June 7, 2011Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Enrollment
1,000

Study Overview

Brief Summary

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
Female

Inclusion Criteria

  • 1. Have signed a consent form before undergoing any trial-related activities
  • 2. Have a confirmed viable pregnancy of less than 16 weeks gestation at booking
  • 3. Have a confirmed diagnosis of epilepsy (any syndrome: primary, localised or unclassified)
  • 4. Currently prescribed lamotrigine monotherapy or polytherapy (with carbamazepine, phenytoin or levetiracetam), carbamazepine monotherapy, phenytoin monotherapy or levetiracetam monotherapy
  • 5. Be capable of understanding the information provided, with use of an interpreter if required

Exclusion Criteria

  • 1. Be beyond 16 weeks gestation at booking
  • 2. Documented non-epileptic seizures in the last 2 years
  • 3. Documented of status epilepticus in the last 12 months
  • 4. A history of alcohol or substance abuse or dependence in the last 2 years
  • 5. Sodium valproate (VPA) monotherapy or polytherapy
  • 6. Non lamotrigine polytherapy
  • 7. A history of poor AED adherence
  • 8. Unable to complete a seizure diary or recall frequency of seizures accurately
  • 9. Have a significant learning disability
  • 10. Participation in any blinded, placebo-controlled trials of investigational medicinal products in pregnancy

Investigators

Similar Trials